Susquehanna International Group
GTBP icon

Susquehanna International Group’s GT Biopharma GTBP Stock Holding History

Susquehanna International Group’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-22
Closed -$111K – 13411
2021
Q3 		$111K Buy
+22
New +$166K ﹤0.01% 11998

Other funds holding GTBP

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Susquehanna International Group's GTBP Position: Q4 2024 in Review

Susquehanna International Group sold out of GT Biopharma (GTBP) in Q4 2024, closing a stake of 404 shares — an estimated $23.1K sold.

Susquehanna International Group first reported a position in GTBP in Q3 2021 and held it in 9 quarters. The position peaked at $312K in Q3 2021. 13 funds tracked by Wall St. Rank hold GTBP as of Q4 2024.

  • Susquehanna International Group reported no remaining GT Biopharma position as of Q4 2024 after selling out during the quarter.
  • Susquehanna International Group sold 404 GT Biopharma shares in Q4 2024, an estimated $23.1K.
  • Susquehanna International Group first reported a position in GT Biopharma in Q3 2021 and held it in 9 quarters.
  • Susquehanna International Group's GT Biopharma position peaked at $312K in Q3 2021.
  • 13 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2024.

Based on Susquehanna International Group's 13F filing for Q4 2024, filed 14 Feb 2025.